explore -WSS

explore

author：explore 2025-08-12 11:28:30 - browse：6158

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Nonprofit, backed by Microsoft, to certify AI tools in health care

knowledge

WSS

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Measles policy set amid Florida outbreak alarms vaccine proponents

Arena BioWorks launches in Cambridge to speed drug discovery

Study suggests new cause of Down syndrome: cells linked to aging

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

explore

explore

explore

Continuity nursing helped my family in our darkest PICU moments

Medicare Advantage coverage denials need scrutiny, senators say

After affirmative action ruling, medical educators look to 'holistic review'

Hospital chaplains balance Covid safety with patients’ spiritual needs

Psychedelics group wrestles with new pharma identity

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Nonprofit, backed by Microsoft, to certify AI tools in health care

Sports medicine is finally prioritizing gender equality

New study raises questions about niacin and heart health

hotspot

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

As AI regulations shape up, health tech startups beg for clarity

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Weight loss drugs aren’t covered by Obamacare. That may change

entertainment

knowledge

hotspot

leisure time